We use cookies to offer you a better online experience, analyze site traffic, and serve targeted advertisements. By continuing to use this website, you consent to our use of cookies in accordance with our cookie and Privacy Policy.
*LDL-C changes from baseline (LS mean) in 053 Trial: NEXLIZET: -36% (n=86); placebo: +2% (n=41) (P<0.001).
LDL-C changes from baseline (LS mean) for other drugs in the trial: bempedoic acid: -17% (n=88); ezetimibe: -23% (n=86).1
AR=adverse reaction; LDL-C=low-density lipoprotein cholesterol; LS=least squares.
Learn more about the Phase 3 trial and the efficacy of adding NEXLIZET
Find out about savings for your eligible patients
References: 1. NEXLIZET. Prescribing information. Esperion Therapeutics, Inc.; 09/2021. 2. Data on file. CSR 1002-053. January 2019. 3. Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022-1032. 4. Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780-1788.
The link you have selected will take you away from NEXLIZETHCP.com to an external website.
ESPERION Therapeutics, Inc. does not endorse and is not responsible for the content included on, or the way in which information is processed by, external websites. Linking to third-party sites is at your own risk. Your use of third-party websites is subject to the terms and conditions and the privacy policies of those individual sites.